본문 바로가기

항암치료에서 약사처방중재의 경제적 편익분석

Assessment of Economic Benefit of Clinical Pharmacy Services in Oncology

문서 유형
연구출판물 · 학술지 논문
등재
KCI
저널
약 학 회 지(약학회지)64(3) · pp.219 · 2020
피인용
KCI 2
ISSN
0377-9556

저자

  1. 김귀숙제1저자덕성여자대학교
  2. 서성연서울대학교병원
  3. 임정미서울대학교병원
  4. 이주연서울대학교
  5. 고영일서울대학교병원
  6. 서혜선교신저자부산대학교

초록

This study analyzed the economic benefits of pharmacists’ prescription intervention in appropriate chemotherapeuticefficacy and safety. We analyzed the types of prescription interventions and the severities of prescription errors byreviewing electronic medical record and intervention reports for anticancer patients from May 1st 2013 through December31st 2014. Total of 114,536 prescriptions were reviewed during the study period and 3,305 (2.9%) prescriptioninterventions were conducted. The evaluation of the economic values for prescription arbitration was calculated by theamount of prevention of drug loss, the risk avoidance cost against inappropriate prescriptions, and the cost of preventingunnecessary preparations. The labor cost of pharmacists for prescription interventions was 15,758,479 won. When weestimated the savings due to pharmacist’s prescription intervention, the cost of risk avoidance of using the Probability ofHarm (POH) resulted from inappropriate prescriptions was estimated to be 2,514,652,575 won. The prevention cost of losswas 586,560,148 won, whereas reduction cost of the unnecessary preparation was 3,944,242 won. Consequently, the netbenefit of clinical pharmacy services in oncology during 20 months was estimated to be 3,089,398,486 won when we usedthe method of POH. Overall, the pharmacist’s prescription arbitration appeared to be beneficial not only for the patient’ssafety but also for the economic benefits.

키워드

oncology servicehospitalpharmacistscost-benefit analysiseconomicpharmaceutical

식별자

KCI
ART002602661